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The majority of colorectal cancer (CRC) cases are preventable by early detection and re-
moval of precancerous polyps. Even though CRC is the second most common internal can-
cer in Australia, only 30 per cent of the population considered to have risk factors participate
in stool-based test screening programs. Evidence indicates a robust, blood-based, diagnos-
tic assay would increase screening compliance. A number of potential diagnostic blood-
based protein biomarkers for CRC have been reported, but all lack sensitivity or specificity
for use as a stand-alone diagnostic. The aim of this study was to identify and validate a
panel of protein-based biomarkers in independent cohorts that could be translated to a reli-
able, non-invasive blood-based screening test.
Principal Findings
In two independent cohorts (n = 145 and n = 197), we evaluated seven single biomarkers in
serum of CRC patients and age/gender matched controls that showed a significant differ-
ence between controls and CRC, but individually lack the sensitivity for diagnostic applica-
tion. Using logistic regression strategies, we identified a panel of three biomarkers that
discriminated between controls and CRC with 73% sensitivity at 95% specificity, when ap-
plied to either of the two cohorts. This panel comprised of Insulin like growth factor binding
protein 2 (IGFBP2), Dickkopf-3 (DKK3), and Pyruvate kinase M2(PKM2).
Conclusions
Due to the heterogeneous nature of CRC, a single biomarker is unlikely to have sufficient
sensitivity or specificity for use as a stand-alone diagnostic screening test and a panel of
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markers may be more effective. We have identified a 3 biomarker panel that has higher sen-
sitivity and specificity for early stage (Stage I and -II) disease than the faecal occult blood
test, raising the possibility for its use as a non-invasive blood diagnostic or screening test.
Introduction
Colorectal cancer (CRC) is the third most common cancer type diagnosed worldwide where it
constitutes approximately 10% of all cancer diagnoses and has an estimated annual mortality
rate over 600,000[1]. Countries such as Australia, New Zealand, Europe, the US, and the UK
are reported to have the highest incidence of disease, however, the incidence is increasing in
countries such as Japan and those of Eastern Europe. The majority of cases (up to 80%) are
sporadic where environmental and lifestyle factors are believed to play a role in its development
[2]. CRC is a heterogeneous disease which develops via an accumulation of genetic mutations
and epigenetic changes in the colonic epithelium that eventually results in neoplastic transfor-
mation [3–5]. The slow and progressive nature of this process presents an opportunity to im-
plement screening programs and diagnostic tools for the early detection of the disease that
have the potential to reduce incidence and mortality associated with CRC. In an attempt to re-
duce incidence and to detect the disease in its early stages before symptoms are evident, screen-
ing programs have been implemented in many countries including the US, UK, Australia,
Japan, and Europe [6–8].
Currently, the most widely used diagnostic tools include endoscopic procedures such as co-
lonoscopy and sigmoidoscopy, and the guaiac-based faecal occult blood test (gFOBT) or the
immunochemical faecal occult blood test (iFOBT), also known as the faecal immune test (FIT)
[9]. While colonoscopy and sigmoidoscopy are the most sensitive procedures for detection of
colorectal tumours and precancerous lesions (adenomas and polyps), and can be potentially
curative if polyps are removed, these procedures are difficult to implement on a population-
wide basis due to cost, invasiveness, expertise required, and time-consuming nature due to the
bowel preparation required [10,11]. While cheap and non-invasive, the FOBT and FIT have
lower sensitivity and specificity than colonoscopy (i.e., these tests have higher false positive
rates) and are most successful at detecting late stage disease [10,12]. Furthermore, the diagnos-
tic performance of FOBT and FIT is variable, with reported sensitivities for CRC between 11–
64% for gFOBT (79–98% specificity) and 56–89% for FIT (83–97% specificity)[13]. These tests
are also often compromised by poor patient compliance, variations in analytical procedures
such as different methods of stool collection and handling, the need for multiple test samples,
and variations in the interpretation of test results [13,14]. Currently, only the gFOBT has been
shown to reduce CRC mortality in large prospective randomised clinical trials [8,13].
Many studies have been published reporting biomarkers that can be implemented as a non-
invasive test to detect CRC, especially in its early stages (Stage I and/or premalignant disease).
A number of strategies for identifying blood-based protein biomarkers have been reported in
the literature, including proteomic and/or gene expression analysis of colorectal tumour tissue
and secreted proteins. Although some of these studies have identified potential panels of pro-
teins or genes suitable for CRC detection [15–19], data from follow-up studies, for instance in
larger patient cohorts, are not available. Currently, the most promising biomarkers appear to
be DNA methylation markers, including methylated septin 9 (mSEPT9) measured in blood
[20–23] and a stool-based DNA test consisting of methylated BMP3, NDRG4, VIM, and
TFPI2 and a mutant form of KRAS[24]. More recently, a modified stool-based DNA test
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consisting of methylated BMP3 and NDRG4, mutant KRAS and ß-actin as the control in com-
bination with faecal haemoglobin was tested in an asymptomatic screening population consist-
ing of 9,989 patients [25]. It was noted that the DNA test had lower specificity, a higher false
positive rate and suffered from a higher technical failure rate due to its complex nature which
may hamper its implementation as a population wide screening test. Although stool-based
DNA tests have shown promising results for CRC detection in clinical trials, they are yet to be
implemented into clinical practice or as a population-wide screening test.
Due to the heterogeneous nature of CRC, a single biomarker is unlikely to have sufficient
sensitivity or specificity for use as a stand-alone diagnostic screening test and a panel of mark-
ers may be more effective. Previously, we evaluated the performance and suitability of 32 pro-
tein biomarkers in the serum and/or plasma of colorectal cancer patients and normal controls
[26]for their ability to diagnose CRC. Although this analysis identified 12 protein biomarkers
that differed significantly between the two groups, no one protein had adequate sensitivity and
specificity for use as a stand-alone diagnostic. We also identified potential biomarker combina-
tions representing different aspects of the disease process that could lead to a diagnostic test for
CRC. Here we report on the evaluation of seven of these protein biomarkers (IGFBP2, PKM2,
DKK3, MAC2BP, tissue inhibitors of metalloproteinases 1 (TIMP1), Interleukin 8 (IL8) and
Interleukin 6 (IL6) as a potential diagnostic or screening test for CRC.
Materials and Methods
Ethics Statement
All research protocols used in this study was approved by the relevant Human Research Ethics
Committees at Commonwealth Scientific Industrial Research Organisation, Adelaide (CFNS
Human Research Ethics Committee-Proposal 03/17 (a) & (b)), and the Royal Melbourne Hos-
pital, Melbourne (HREC project 2003.145 & 2003.146). Written informed consent was ob-
tained from each patient prior to blood sample collection.
Sample collection
Patients were newly diagnosed cases of CRC with no previous history of disease. Blood was ob-
tained prior to surgery at colorectal surgery preadmission clinics from a network of hospitals
associated with the Victorian Cancer Biobank, Melbourne, Victoria, Australia, between 2005
and 2011. Patients who had already received chemo- and/or radio- therapy were excluded
from this study. For CRC patients, blood samples were taken after diagnosis and at least one
day before surgery. Staging was conducted according to the TNM classification for colon and
rectal cancer [27].
Serum samples from CRC patients and age/gender matched controls were collected using a
standard operating procedure as previously described [28,29]. Blood was collected into serum
gel tubes (Scientific Specialties Inc., USA) and each sample was left to stand at room tempera-
ture for 30 min prior to centrifugation (1,200g, 10 min, room temperature). The serum fraction
was then transferred to clean 15 mL tubes and centrifuged again (1,800g, 10 min, room temper-
ature) prior to being aliquotted (250 μL) and stored (−80°C). All samples were processed and
stored within 2 hrs of collection.
Biomarker analysis and identification of the biomarker panel
The following biomarkers were measured using commercially available ELISA kits according
to the respective manufacturer protocols: IGFBP2 (Diagnostic Systems Laboratories, USA or
Demeditec Diagnostics GmbH, Germany), MAC2BP (Bender MedSystems GmbH, Austria),
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PKM2 (Schebo Biotech, Germany), DKK3 (R&D Systems, USA) and TIMP1 (R&D Systems,
USA). IL6 and IL8 were analysed as bead-based assays sourced from R&D Systems (Minneapo-
lis, MN, USA). For each assay, samples were measured in duplicate and in-house quality con-
trol (QC) samples were included. QC samples consisted of a pooled normal sample (n = 41)
and pooled CRC patient sample (n = 41). For each assay, the inter- and intra-assay coefficients
of variation (CV) were less than 10%. This is consistent with the manufacturer specifications.
For the standard ELISAs, the absorbance or fluorescence signal was detected using the Wal-
lac Victor3 1420 multilabel counter (Perkin Elmer, USA). Biomarker concentrations were de-
rived from the respective standard curve using the WorkOut software (version 2.0). For IL8
and IL6, preliminary data was analysed using the Luminex IS2.3 software (Qiagen, Hilden,
Germany).
The Prism software package (v6, Graphpad Software Inc., San Diego, CA, USA) and the R
statistical software packages were used for statistical analysis. The non-parametric Wilcoxon
rank sum test was used to determine the statistical difference between cancer and control pa-
tients, and receiver operator characteristic (ROC) curve analysis was performed to assess the
diagnostic performance for each marker and to determine the sensitivity for each at 95% speci-
ficity. Bootstrap confidence intervals with 20,000 bootstrap resamples for area under the curve
(AUC) was performed using the R package pROC [30].
Biomarkers were selected for the panel using forward stepwise variable selection and Bayes-
ian information criterion (BIC) penalty to prevent over-fitting. This process of variable selec-
tion and estimation of coefficients was performed in Cohort 1 (training data set) and then to
Cohort 2 (test data set). The model was then applied to both cohorts to identify the best per-
forming panels that cross validated.
Results
Performance of individual biomarkers measured in the serum of CRC
and control patients
The clinical characteristics for the patient cohorts are shown in Table 1. The levels of all seven
proteins differed significantly between the patient and control groups in both the training and
test cohorts (Table 2 and S1 Fig.). With the exception of DKK3, all markers were elevated in
the patient group. ROC analysis was also performed to determine the ability of each protein to
discriminate between the patient and control groups (Table 3 and S2 Fig.). PKM2 was the best
performing biomarker with a sensitivity of 56% (p<0.0001) and 59% (p<0.0001) at 95% speci-
ficity for CRC overall when measured in the training and test cohorts, respectively. Similarly,
PKM2 also proved to be the most successful marker at identifying CRC at each disease stage
when compared to the control population in this particular study, including early stage disease
(sensitivities of 48% (p = 0.0008), 52% (p<0.0001), 61% (p<0.0001) and 75% (p<0.0001) for
Stages I, II, III and IV, respectively in the training cohort and sensitivities of 52% (p<0.0001),
65% (p<0.0001), 54% (p<0.0001) and 80% (p<0.0001) for Stages I, II, III and IV, respectively
in the test cohort) (S1 Table). The performance characteristics of individual biomarkers in the
training and test cohorts can be found in S1 Table. When considered individually, none of
these biomarkers had sufficient sensitivity to diagnose CRC.
Identification of a three-biomarker panel for CRC diagnosis
Using forward stepwise logistic regression applied to the training data set (Cohort 1), a three
biomarker model consisting of DKK3, PKM2 and IGFBP2 was identified that could diagnose
CRC with 73% sensitivity at 95% specificity (Table 4). Furthermore, this three-biomarker
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model proved to be robust when validated in the test cohort (Cohort 2, sensitivity of 73% at
95% specificity), and was able to discriminate between controls and CRC patients at different
TNM stage with similar sensitivity (Table 4). Importantly, this biomarker model is able to iden-
tify patients with early stage disease with high sensitivity (i.e., 57% and 76% sensitivity, at 95%
specificity for Stages I and II, respectively, in the training cohort and 59% and 84% for Stages I
and II, respectively, in the test cohort). Fig. 1 shows the ROC curve for the three-biomarker
model and the performance characteristics of the model is detailed in Table 4.
Discussion
Previously, we measured 32 protein biomarkers in the plasma and sera of CRC patients and
controls [26]. These biomarkers were initially identified as being potentially useful for CRC di-
agnosis based on biology, gene expression microarray and proteomic data, from both our own
studies and from the literature. In our previous study, we measured PKM2 in plasma and deter-
mined that it had 19% sensitivity (at 95% specificity) whereas in serum we observed sensitivity
of 56% at 95% specificity. When measured in serum, PKM2 was the best performing biomarker
for CRC diagnosis when compared to the other biomarkers we measured. Furthermore, it was
also the best performing marker when distinguishing early stage disease (48% sensitivity). As a
further extension to this study, we have undertaken further evaluation of seven of these pro-
teins in two independent case control cohorts (Cohort 1 and 2). Furthermore, we have
Table 1. Characteristics of the colorectal cancer and normal patients used in this study cohort.
Cohort 1 (Training data set) Cohort 2 (Test data set)
Characteristics Control Colorectal cancer Control Colorectal cancer
N 50 95 99 98
Gender, N
Female 25 50 33 34
Male 25 45 66 64







Table 2. Concentration (median and range) for individual protein biomarkers measured in the serum of cancer and control patients.
Cohort 1 (Training data set) Cohort 2 (Test data set)
Control Colorectal cancer P value Control Colorectal cancer P value
PKM2 (U/mL) 80.16 (31.20–171.2) 161.2 (32.72–392.3) <0.0001 46.43 (15.16–125.8) 127.3 (29.78–345.8) <0.0001
IL6 (pg/mL) 1.210 (0.2700–4.740) 1.745 (0.5–55.80) <0.0001 1.590 (0.2500–48.98) 2.850 (0.3800–186.9) <0.0001
DKK3 (pg/mL) 37407 (20714–529848) 30303 (10367–353232) 0.0004 32169 (13775–144377) 28354 (11208–94505) 0.0042
IL8 (pg/mL) 11.26 (4.360–49.89) 15.75 (3.710–103.5) 0.0006 9.735 (4.640–41.73) 16.05 (4.240–675.5) <0.0001
IGFBP2 (ng/mL) 430.3 (132.9–1029) 513.1 (186.0–9347) 0.0006 469.2 (137.6–1206) 554.2 (135.0–2031) 0.0121
Mac2BP (ng/mL) 7126 (3918–20150) 8350 (4290–40870) 0.0008 4987 (1842–29691) 6481 (2568–20218) <0.0001
TIMP1 (ng/mL) 166.6 (126.4–248.7) 187.1 (101.0–497.6) 0.0235 184.9 (107.0–315.5) 205.9 (121.1–875.2) 0.0002
doi:10.1371/journal.pone.0120425.t002
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identified a panel of three protein biomarkers that is able to diagnose CRC from a control pop-
ulation with 73% sensitivity at 95% specificity in both the training (n = 145) and test (n = 197)
cohorts in our study. Although these initial studies are promising, we are currently undertaking
further testing of our biomarker panel in a patient cohort which includes non-malignant colo-
rectal diseases (e.g., inflammatory bowel disease, diverticulutis), adenomas, benign and/or pre-
cancerous polyps and other cancers. This will enable us to determine the specificity of the
panel for CRC detection and its sensitivity for early stage or premalignant disease.
Our three biomarker panel consists of IGFBP2, DKK3 and PKM2, and each of these pro-
teins are known to be biologically important in CRC disease and progression and are represen-
tative of the heterogeneous nature of this cancer. For example, there are numerous reports
indicating the involvement of IGFBP2 in proliferation, migration and invasion of cancer cells
[31], and elevated levels of IGFBP2 have also been reported in the serum and plasma of CRC
patients when compared to normal controls [32–35]. Transcriptional silencing of DKK3 due to
promoter hypermethylation in CRC tissue has been reported [36,37], and this may explain the
Table 3. Classiﬁcation performance of the seven protein biomarkers in the training and test cohorts.
Cohort 1 (Training data set) Cohort 2 (Test data set)
AUC p value Sensitivity (%) at 95%
speciﬁcity
Cutoff AUC p value Sensitivity (%) at 95%
speciﬁcity
Cutoff
PKM2 (U/mL) 0.82 (0.76–
0.85)
<0.0001 56 >140.7 0.91 (0.88–
0.94)
<0.0001 59 >107.9
IL6 (pg/mL) 0.70 (0.61–
0.76)
0.0002 27 >2.895 0.75 (0.67–
0.80)
<0.0001 27 >4.790
DKK3 (pg/mL) 0.68 (0.61–
0.75)
0.0004 19 <23048 0.62 (0.55–
0.68)
0.0042 11 <18262
IL8 (pg/mL) 0.68 (0.59–
0.74)





















0.0236 20 >237.2 0.65 (0.60–
0.70)
0.0002 15 >265.6
Abbreviations: AUC, area under the receiver operating characteristic curv
doi:10.1371/journal.pone.0120425.t003
Table 4. Performance characteristics of the three-biomarker model (DKK3, IGFBP2 and PKM2).
CRC all disease
stages
Stage I Stage II Stage III Stage IV




































73 73 57 59 76 84 76 71 88 78
P value <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001 <0.0001
Abbreviations: CRC, colorectal cancer; ROC, receiver operating characteristic
doi:10.1371/journal.pone.0120425.t004
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decreased levels in the serum of CRC patients we observed in this study. However, an elevated
protein expression level in the endothelial cells of microvessels of cancer tissue has also been re-
ported indicating the potential importance of DKK3 in CRC progression, due to angiogenesis
and neovascularisation [38]. PKM2 is a cytosolic enzyme involved in energy metabolism that is
expressed by both normal proliferating cells and cancer cells. Elevated expression of the tu-
mour-specific dimeric form of this protein has been reported in CRC and other gastrointestinal
cancers [39–41] and numerous studies have evaluated its usefulness as a faecal or blood-based
marker for CRC screening and/or diagnosis [40,42–46]. The primary disadvantage concerning
its utility as a stand-alone diagnostic marker has been its poor specificity for CRC.
The performance of the three-biomarker model consisting of IGFBP2, DKK3 and PKM2
(73% sensitivity at 95% specificity) is equivalent to that quoted for FOBT and FIT (sensitivity
61–79% at 86–95% specificity) [12,14,47–49]. Furthermore, the panel of biomarkers that we
have identified appears to perform well for early stage disease detection (i.e., Stage I and II dis-
ease). This superior performance at early stages, particularly at Stage I, provides an important
advantage of our biomarker panel over currently used non-invasive tests for CRC. This is an
important consideration since early disease detection and appropriate patient management im-
proves overall survival for this disease. Further testing of the panel in a large prospective co-
hort, which includes patients with high-risk adenomas or polyps, is needed to fully understand
the potential utility of our panel for diagnostic or screening purposes. It is also possible that the
biomarker panel can be used in combination with current screening modalities, such as FOBT,
FIT, or the recently reported plasma mSEPT9 test or stool-based DNAmarkers [20–24] to fur-
ther improve diagnostic performance.
Fig 1. Receiver operator characteristic (ROC) curves by AJCC TNM stage for the three biomarker
model, fitted to the training data, and applied to both training and test data.
doi:10.1371/journal.pone.0120425.g001
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While it is known that screening programs can reduce mortality from CRC, emerging evi-
dence suggests that a non-invasive blood-based test with high sensitivity and specificity for the
disease, in particular early stage disease, may be advantageous to overcome perceived barriers
to participation associated with the use of FOBT [50,51]. While non-invasive, the FOBT is not
specific for CRC and it is not able to accurately detect early stage disease. Furthermore, the
value of this test is hampered by poor patient compliance [50]. Data from studies which evalu-
ate patient preference for blood testing versus endoscopy, including colonoscopy or sigmoidos-
copy, are not available. However, studies investigating patient preference between FOBT and
colonoscopy show conflicting results. For instance, Schroy et al. indicate that patients have a
preference for faecal testing for routine screening due to its convenience and non-invasive na-
ture [52]. Another study by Hol et al. concluded that screening using endoscopy techniques
were preferable amongst a screening population due to the certainty of diagnosis and reduction
in risk of disease [53]. This indicates that to be successfully implemented in the community,
high sensitivity and specificity to accurately and reliably diagnose CRC and inform patient fol-
low-up procedures are important features of any diagnostic test that must be considered.
Supporting Information
S1 Fig. Scatter plots for the seven biomarkers evaluated in the training and test cohorts.
(PDF)
S2 Fig. Receiver operator characteristic curves for the seven biomarkers evaluated in the
training and test cohorts.
(PDF)
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